These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 28667569

  • 21. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
    Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J, 316 Study Group.
    Behav Brain Funct; 2010 Jun 24; 6():34. PubMed ID: 20576091
    [Abstract] [Full Text] [Related]

  • 22. Parent-reported executive function behaviors and clinician ratings of attention-deficit/hyperactivity disorder symptoms in children treated with lisdexamfetamine dimesylate.
    Findling RL, Adeyi B, Dirks B, Babcock T, Scheckner B, Lasser R, DeLeon A, Ginsberg LD.
    J Child Adolesc Psychopharmacol; 2013 Feb 24; 23(1):28-35. PubMed ID: 23410139
    [Abstract] [Full Text] [Related]

  • 23. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.
    Weisler R, Young J, Mattingly G, Gao J, Squires L, Adler L, 304 Study Group.
    CNS Spectr; 2009 Oct 24; 14(10):573-85. PubMed ID: 20095369
    [Abstract] [Full Text] [Related]

  • 24. SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results of a Randomized, Double-Blind Placebo-Controlled Study.
    Brams M, Childress AC, Greenbaum M, Yu M, Yan B, Jaffee M, Robertson B.
    J Child Adolesc Psychopharmacol; 2018 Feb 24; 28(1):19-28. PubMed ID: 28816509
    [Abstract] [Full Text] [Related]

  • 25. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J.
    Clin Ther; 2009 Jan 24; 31(1):142-76. PubMed ID: 19243715
    [Abstract] [Full Text] [Related]

  • 26. Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
    Mattingly GW, Weisler RH, Young J, Adeyi B, Dirks B, Babcock T, Lasser R, Scheckner B, Goodman DW.
    BMC Psychiatry; 2013 Jan 29; 13():39. PubMed ID: 23356790
    [Abstract] [Full Text] [Related]

  • 27. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
    Najib J, Didenko E, Meleshkina D, Yusupov K, Maw K, Ramnarain J, Tabassum M.
    Curr Med Res Opin; 2020 Oct 29; 36(10):1717-1735. PubMed ID: 32845786
    [Abstract] [Full Text] [Related]

  • 28. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.
    J Clin Psychiatry; 2012 Jul 29; 73(7):977-83. PubMed ID: 22780921
    [Abstract] [Full Text] [Related]

  • 29. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
    Dittmann RW, Cardo E, Nagy P, Anderson CS, Adeyi B, Caballero B, Hodgkins P, Civil R, Coghill DR.
    CNS Drugs; 2014 Nov 29; 28(11):1059-69. PubMed ID: 25038977
    [Abstract] [Full Text] [Related]

  • 30. Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.
    Turgay A, Ginsberg L, Sarkis E, Jain R, Adeyi B, Gao J, Dirks B, Babcock T, Scheckner B, Richards C, Lasser R, Findling RL.
    J Child Adolesc Psychopharmacol; 2010 Dec 29; 20(6):503-11. PubMed ID: 21186969
    [Abstract] [Full Text] [Related]

  • 31. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
    Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL.
    Clin Ther; 2007 Mar 29; 29(3):450-63. PubMed ID: 17577466
    [Abstract] [Full Text] [Related]

  • 32. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design.
    Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS, Civil R, Dauphin M, Higgins N, Lyne A, Gasior M, Squires LA.
    J Am Acad Child Adolesc Psychiatry; 2014 Jun 29; 53(6):647-657.e1. PubMed ID: 24839883
    [Abstract] [Full Text] [Related]

  • 33. A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder.
    Gasior M, Hudson J, Quintero J, Ferreira-Cornwell MC, Radewonuk J, McElroy SL.
    J Clin Psychopharmacol; 2017 Jun 29; 37(3):315-322. PubMed ID: 28383364
    [Abstract] [Full Text] [Related]

  • 34. Treatment outcomes with lisdexamfetamine dimesylate in children who have attention-deficit/hyperactivity disorder with emotional control impairments.
    Katic A, Dirks B, Babcock T, Scheckner B, Adeyi B, Richards C, Findling RL.
    J Child Adolesc Psychopharmacol; 2013 Aug 29; 23(6):386-93. PubMed ID: 23952185
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.